Navigation Links
Blood-thinning copycat enters malaria fight
Date:6/1/2010

New treatments for malaria are possible after Walter and Eliza Hall Institute scientists found that molecules similar to the blood-thinning drug heparin can stop malaria from infecting red blood cells.

Malaria is an infection of red blood cells that is transmitted by mosquitoes. The most common form of malaria is caused by the parasite Plasmodium falciparum which burrows into red blood cells where it rapidly multiplies, leading to massive numbers of parasites in the blood stream that can cause severe disease and death.

At the moment, all anti-malarials licensed for use in humans block the development of the parasite within the red blood cell.

But Dr James Beeson, Ms Michelle Boyle and Dr Jack Richards from the institute's Infection and Immunity division, along with colleagues at the Burnet Institute and Imperial College London, have identified a new approach that could stop the parasite infecting red blood cells in the first place.

Using real-time video microscopy of red blood cell infection, the team showed that heparin-like carbohydrates blocked the ability of the malaria parasite to infect cells, Dr Beeson said.

"The malaria parasite needs a protein called MSP1 if it is to infect red blood cells as MSP1 is involved in the initial attachment of the parasite to the cells," Dr Beeson said.

"We have shown that heparin-like carbohydrates bind to MSP1 which stops the parasite from properly attaching to the red blood cell and, therefore, from invading."

The findings are published today in the international journal Blood and have raised the prospect of developing new anti-malarials that are based on the structure and activity of heparin-like molecules.

Although humans produce heparin-like molecules naturally, they do not occur at high enough levels in the blood to have anti-malarial activity, Dr Beeson said. "Heparin itself wouldn't be suitable as an anti-malarial as it prevents blood clotting. However, we have identified related compounds that are more potent against malaria than heparin but do not prevent blood clotting- these could form the basis of new antimalarial drugs."

Each year more than 400 million people contract malaria, and around one million people, mostly children, die from the disease.


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-417-125-700
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. New blood-thinning drug safer than rat poison
2. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
3. DFG to establish 10 new collaborative research centers
4. US and UK research centers launch major collaboration on atmospheric research, technology
5. AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands
6. Weight Watchers vs. fitness centers
7. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
8. NSF and EPA establish 2 centers for environmental implications of nanotechnology
9. Sicilian word enters British genetic language
10. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers
11. Tellme Enters Automotive Market
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood-thinning copycat enters malaria fight
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology: